Refusal of orphan designation for treatment of carcinoma in situ of the urinary bladder
Mycobacterial cell wall complex
OrphanHuman
On 12 September 2002, the Committee for Orphan Medicinal Products (COMP) adopted a negative opinion on orphan designation for Mycobacterial cell wall complex in the treatment of superficial bladder cancer. A negative decision was granted by the European Commission on 18 December 2002.
The sponsor, Bioniche Teoranta Ireland, applied for orphan designation of mycobacterial cell wall complex for treatment of carcinoma in situ of the urinary bladder. This application was based on the severity and rarity of the condition, as well as an assumption of potential benefit despite currently available methods of treatment.
The negative opinion is based on the following grounds:
Requests for designation as orphan medicinal products are made for investigational products. Absence of orphan designation does not preclude the development of this product, in particular through clinical trials, and subsequently the possibility of obtaining a marketing authorisation if quality, safety and efficacy are demonstrated.
Bioniche Teoranta
Inverin
County Galway
Ireland
Tel. +353 9159 3202
Fax +353 9159 3228
E-mail: marc.riviere@bioniche.com
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: